SYNCAR-001

Phase 1Small molecule

SSynthekine

SYNCAR-001 is one of 93 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Rheumatic DiseaseActive, not recruiting

CLL/SLLActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Rheumatic DiseasePhase 1

Active, not recruiting

CLL/SLLPhase 1

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

9 2

Medrol

Pfizer

Phase 3

5 3

Stelara

Johnson & Johnson

Phase 3

3 4

Rinvoq

AbbVie

Phase 3

3 5

Gazyva

Roche

Phase 3

2 6

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 7

Rayos

RRoxane Laboratories

Phase 3

6 8

Benadryl

PParkedale

Phase 3

3 9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 10

Tylenol

KKenvue Brands

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2041

Phase 1Active, not recruiting

Systemic Lupus Erythematosus

NCT06544330

Q4 2041

Phase 1Active, not recruiting

CLL/SLL

NCT05665062

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

A Phase 1, Open-Label Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

Active, not recruiting·SSynthekine·Phase 1·NCT06544330·48 enrolled

CLL/SLL1 trial

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies

Active, not recruiting·SSynthekine·Phase 1·NCT05665062·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SYNCAR-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SYNCAR-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SYNCAR-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Synthekine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSynthekine

SYNCAR-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2041

Q4 2041

Trials by Indication[1]

Systemic Lupus Erythematosus1 trial

CLL/SLL1 trial

References

Drug Info

Quick Facts

Related News